Published March 2011 | Version v1
Journal article

Original Article Did salvage ICE chemotherapy improve the outcome in primary resistant/relapsing stage Ill/TV neuroblastoma

  • 1. Pediatric Oncology Department, National Cancer Institute (NC1), Cairo University and Children Cancer Hospital, Cairo (Egypt)
  • 2. Pediatric Oncology Department, Menufeya University and Children Cancer Hospital Egypt, Cairo (Egypt)
  • 3. Radiotherapy Department, National Cancer Institute (NCf) and Children Cancer Hospital Egypt (CCHE), Cairo (Egypt)
  • 4. Pathology Department, National Cancer Institute (NCI) and Children Cancer Hospital Egypt (CCHE), Cairo (Egypt)
  • 5. Surgical Oncology Department, National Cancer Institute (NCI) and Children Cancer Hospital Egypt (CCHE), Cairo (Egypt)
  • 6. Public Health Department, National Liver Institute, Menufeya University and Children Cancer Hospital Egypt (CCHE), Cairo (Egypt)
  • 7. Clinical Research Department, Children Cancer Hospital Egypt (CCHE), Cairo (Egypt)

Description

Neuroblastoma is the most common extracranial and deadly solid tumor in children. It accounts for 15% of the deaths from cancer in the pediatric age group. Approximately half of the newly diagnosed children are at high riskof treatment failure. The aim of this study is to evaluate the response rate of salvage chemotherapy by the ICE (Ifosfamide, Carboplatin, and Etoposide) regimen when administered to previously treated primary refractory or progressive high risk neuroblastoma patients. Patients and methods: Sixty-six patients from the National Cancer Institute (NCI), Cairo University and the Children Cancer Hospital Egypt (CCHE) received salvage chemotherapy (ICE) either due to primary resistance in 51/66 (77.2%) or due to disease progression on primary chemotherapy in 15/66 (22.8%). Results: They were 40 males (60.6%) and 26 females (39.4%). Patients' age ranged between 3 months and 12.5 years. The most common tumor site was suprarenal, followed by retroperitoneal mass. Two patients (3%)'died from chemotherapy toxicity during ICE administration. Evaluation of tumor response in the remaining 64 patients showed the following: CR/PR in 24 patients (36.5%), SD in 11 patients (16.6%), and PD in 29 patients (43.9%). Fourteen patients (21.2%) were considered eligible for auto BMT, while 50/64 patients (78.8%) failed this second line (salvage) chemotherapy and had palliative lines of therapy. By the end of the study (May 2010), 47/66 (71.2%) of the patients were still alive, while 19/66 (28.8%) were dead. Two out of 14 patients (14.2%) who underwent HSCT died from post transplantation disease progression, while 12/14 (85.8%) were in CCR. Conclusion: Chemotherapy by ICE for primary resistant or progressive stage III/IV NB seems well tolerated. With a 36.6% response rate, 18% CCR, and 3% treatment mortality rate, it could be considered a good salvage therapy in the category of patients who are condemned for palliation

Additional details

Publishing Information

Journal Title
Journal of the Egyptian National Cancer Institute
Journal Volume
23
Journal Issue
1
Journal Page Range
p. 47-53
ISSN
1110-0362

INIS

Country of Publication
Egypt
Country of Input or Organization
Egypt
INIS RN
45105926
Subject category
S62: RADIOLOGY AND NUCLEAR MEDICINE;
Descriptors DEI
CHEMOTHERAPY; CHILDREN; NEOPLASMS; NERVE CELLS; PATIENTS
Descriptors DEC
AGE GROUPS; ANIMAL CELLS; ANIMALS; DISEASES; MAMMALS; MAN; MEDICINE; PRIMATES; SOMATIC CELLS; THERAPY; VERTEBRATES